Evidence map›Paper›PMID 42527451›Full record

ArticleScientific reports2026

Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model.

Robert Polten, Ivana Kutle, Jan Lennart Stalp, Jens Hachenberg, Philipp John-Neek, Ann-Kathrin Seyda, Dhanya Ramachandran, Rafaela Schmidtke, Valeriia Obrizan, Lara Kokemüller and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Robert PoltenInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Ivana KutleInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Jan Lennart StalpInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Jens HachenbergInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Philipp John-NeekInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Ann-Kathrin SeydaInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Dhanya RamachandranDepartment of Gynecology and Obstetrics, Hannover Medical School, 30625, Hannover, Germany.
Rafaela SchmidtkeDepartment of Gynecology and Obstetrics, Hannover Medical School, 30625, Hannover, Germany.
Valeriia ObrizanDepartment of Gynecology and Obstetrics, Hannover Medical School, 30625, Hannover, Germany.
Lara KokemüllerDepartment of Gynecology and Obstetrics, Hannover Medical School, 30625, Hannover, Germany.
Doris SteinemannDepartment of Human Genetics, Hannover Medical School, 30625, Hannover, Germany.
Jonathan LühmannDepartment of Human Genetics, Hannover Medical School, 30625, Hannover, Germany.
Yvonne Lisa BehrensDepartment of Human Genetics, Hannover Medical School, 30625, Hannover, Germany.
Gudrun GöhringDepartment of Human Genetics, Hannover Medical School, 30625, Hannover, Germany.
Stephan BartelsInstitute of Pathology, Hannover Medical School, 30625, Hannover, Germany.
Malte GronewoldInstitute of Pathology, Hannover Medical School, 30625, Hannover, Germany.
Lavinia NeubertInstitute of Pathology, Hannover Medical School, 30625, Hannover, Germany.
Jan C KampBiomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), 30625, Hannover, Germany.
Dirk SchaudienFraunhofer Institute for Toxicology and Experimental Medicine, ITEM, 30625, Hannover, Germany.
Robert GeffersGenome Analytics, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany.
Peter HillemannsDepartment of Gynecology and Obstetrics, Hannover Medical School, 30625, Hannover, Germany.
Thilo DörkDepartment of Gynecology and Obstetrics, Hannover Medical School, 30625, Hannover, Germany.
Rüdiger KlapdorInstitute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Michael Morgan *Institute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany. Morgan.michael@mh-hannover.de.
Axel Schambach *Institute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany. Schambach.axel@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic profiling of a new HPV-negative cervical cancer model identified pathogenic variants in genes implicated in oncogenic signaling, cell cycle regulation, and DNA damage repair pathways, including homologous recombination, non-homologous end-joining, and mismatch repair. Deficiencies in BRCA2, RAD51 and MLH1 were among these actionable targets. The newly described cervical cancer model revealed sensitivity towards the PARP inhibitor olaparib, which was further augmented upon combination with platinum-based chemotherapeutics. In contrast, BRCA1/2-proficient cervical cancer cells exhibited greater resistance to these strategies. This study highlights the potential of in-depth genetic analysis to identify genetic susceptibilities to guide personalized medicine approaches.

Indexed as

DNA RepairUterine Cervical NeoplasmsBRCA1 ProteinBRCA2 ProteinCell Line, TumorDNA DamageFemaleGene Expression ProfilingHumansMutL Protein Homolog 1PhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRad51 RecombinaseBRCA1 ProteinBRCA2 ProteinMLH1 protein, humanMutL Protein Homolog 1olaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsRAD51 protein, humanRad51 RecombinaseCervical cancerDNA damageHPV-negativePARP inhibitorTargeted therapy

Identifiers

PMID42527451
PMCPMC13421491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.